Patients with MTUS1 expressing tumours also had better progression-free survival (PFS, mean survival time: 60.5 months, n = 111) compared to patients with MTUS1 expression loss (46.8 months, n = 86, p = 0.179, PFS graphs not shown). The gene discussed is MTUS1; the disease is neoplasm.